Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Metastatic melanoma with measurable disease.~ 2. Previously received high dose aldesleukin (IL-2) and have been either non-responders (progressive disease) or have recurred.~ 3. Positive for gp100 by immunohistochemistry (IHC).~ 4. Greater than or equal to 18 years of age.~ 5. Willing to sign a durable power of attorney.~ 6. Able to understand and sign the Informed Consent Document.~ 7. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.~     h Life expectancy of greater than three months.~  i. Patients of both genders must be willing to practice birth control for four months after receiving the preparative regimen.~  j. Must be human leukocyte antigen (HLA-A 0201) positive~  k. Serology:~ 1. Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune -competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.)~ 2. Seronegative for hepatitis B antigen and hepatitis C antibody unless antigen negative.~  l. Hematology:~ 1. Absolute neutrophil count greater than 1000/mm\^3.~ 2. White blood cell (WBC) (greater than 3000/ mm\^3).~ 3. Platelet count greater than 100,000/ mm\^3.~ 4. Hemoglobin greater than 8.0 g/dl.~  m. Chemistry:~ 1. Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to 2.5 times the upper limit of normal.~ 2. Serum creatinine less than or equal to 1.6 mg/dl.~ 3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.~  n. Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus.~  o. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).~  p. Six weeks must have elapsed since prior cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) antibody therapy to allow antibody levels to decline, and patients who have previously received must have a normal colonoscopy with normal colonic biopsies.~EXCLUSION CRITERIA:~1. Patients with reactive TIL (interferon (IFN)- gamma release greater than 200 pg/mL) available based on overnight co-culture assay with autologous tumor or MHC-matched tumor cells.~2. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.~3. Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.~4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).~5. Opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)~6. Systemic steroid therapy.~7. History of severe immediate hypersensitivity reaction to any of the agents used in this study.~8. History of coronary revascularization.~9. Documented left ventricular ejection faction (LVEF) of less than 45 percent in patients with:~a. Clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, 2 degree or 3 degree heart block.~b. Age greater than or equal to 60 years old.~j. Documented forced expiratory volume 1 (FEV1) greater than or equal to 60 percent predicted for patients with:~1. A prolonged history of cigarette smoking (greater than 20 pack/year within the past 2 years).~2. Symptoms of respiratory distress.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anti-gp100:154-162 TCR PBL + HD IL-2 (Type: EXPERIMENTAL): 1. fludarabine phosphate-25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days~2. cyclophosphamide-60 mg/kg/day x 2 days intravenous~3. Anti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.~4. aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
- anti-gp100:154-162 TCR TIL + HD IL-2 (Type: EXPERIMENTAL): 1. fludarabine phosphate-25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days~2. cyclophosphamide-60 mg/kg/day x 2 days intravenous~3. Anti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes~4. aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).